SecBot SecBot
Insider Buy ·Filed Nov 13, 2026

CRVS

Corvus Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3d 9h ago SEC0001610717-26-000454
Insider cluster: 1 insiders, $50K total
Actionable Insight • Neutral

The CBO's $50K purchase is small relative to market cap and does not signal a material change in outlook. Monitor next pipeline data readouts (Angel Pharma topline March 2027, HS trial data 1H 2027) as the primary catalysts for CRVS.

DirectionNeutral
Confidencehigh
Horizonweeks

soquelitinib

● Neutral Named in this insider buy
Impact
Phase
Phase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
Time to market
If the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.
Next catalyst
None dated

What to watchThe next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chief Business Officer Jeffrey Arcara purchased a total of $50K in CRVS shares over four open-market trades between Nov 11-13, 2026, with no 10b5-1 plan. The purchases follow the company's Q3 2026 earnings report (Nov 5) which showed a wider net loss but highlighted positive pipeline data for soquelitinib and extended cash runway into Q2 2028.

Key Financial Metrics

Direction
buying
Total Value
$50.5K
Insiders
1

Key Facts

  • Chief Business Officer Arcara purchased 4,500 shares total at prices from $10.37 to $11.46 per share
  • Total purchase value of approximately $50,475
  • All four trades were open-market purchases (Form 4 code P) with no 10b5-1 plan
  • Purchases occurred Nov 11-13, 2026, within 8 days of Q3 2026 earnings release
  • Q3 2026 net loss of $20.3M was wider than $10.2M in Q3 2025, but cash runway extends into Q2 2028
  • Pipeline milestones include positive ALPS Phase 2 data and Angel Pharma cohort 1 enrollment complete

Financial Impact

$50K insider purchase represents approximately 0.005% of $968M market cap

insider ownership

Risk Factors

  • Insider purchase is very small relative to market cap (0.005%), limiting its informational value
  • Company reported a wider net loss in Q3 2026 vs prior year
  • Pipeline-stage biotech with no approved products; clinical trial risks remain

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
INSIDER-BUY Data (Synthetic)0001610717-26-000454

Track record

15 reports on CRVS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 13, 20263d ago Insider Buy Neutral 3/10 Viewing Entry $11.20 Now $10.60 −5.36% settles Feb 12
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $11.37 Now $10.60 −6.77% settles Feb 8
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
  4. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  5. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
  6. Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
  7. Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
  8. Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
  10. May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026